Active Ingredient(s): Sonidegib
FDA Approved: * July 24, 2015
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Odomzo Overview

Sonidegib (INN; also known as LDE225 and erismodegib; trade name Odomzo[3]) is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) being developed as an anticancer agent by Novartis.[4][5] Contents 1 Approvals and indications 2 Pharmacology 3 Development 4 Reference list Approvals and indications It was approved by the FDA for treating basal-cell carcinoma in July 2015[6][3] and is awaiting...

Read more Odomzo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Sonidegib

Recent Odomzo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Capsule: 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Odomzo: (2 results)

Sorted by National Drug Code
  • 0078-0645 Odomzo 200 mg Oral Capsule by Novartis Pharmaceuticals Corporation
  • 47335-303 Odomzo 200 mg Oral Capsule by Sun Pharma Global Fze

Other drugs which contain Sonidegib or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 29 February 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA